New treatment strategies for elderly myeloma patients

A Palumbo; P Falco; P Musto; G Rossi; N Giuliani; F Morabito; A Falcone

doi:10.4081/hmr.v2i7.438

Authors

In the treatment of elderly patients, the new paradigm is the combination of the old drug melphalan with the new drugs thalidomide, lenalidomide or bortezomib. In newly diagnosed multiple myeloma (MM) patients, the combination melphalan, prednisone and thalidomide (MPT) induces a fast tumor response with a high response rate, but evidence that this translate into improved outcome is limited. This multicenter trial compared the efficacy and the toxicity of oral MPT with oral melphalan and prednisone (MP) in previously untreated patients.

Supporting Agencies

Palumbo, A., Falco, P., Musto, P., Rossi, G., Giuliani, N., Morabito, F., & Falcone, A. (2009). New treatment strategies for elderly myeloma patients. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.438

Download Citation

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations